RIVIERA BEACH, Fla., July 23, 2012 /PRNewswire-iReach/ -- Sancilio and Company, Inc. (SCI) is pleased to announce the recent addition of Dr. Alan Dunton, Mr. Patrick Gray, Mr. Rod Jackson, Dr. Dennis Langer and Mr. Kelly Perkins to its Board of Directors. The new directors join the Company's Chairman, Dr. Frederick Sancilio, who is also Founder, President and CEO.
"Our new directors are very well-known in the life sciences and financial industries. Their outstanding credentials, recognized leadership, and depth of executive experience are evidence of SCI's commitment to attract the highest quality leadership available. Each of our new directors is exceptionally well suited to help lead the Company into its next phase, and together will help grow our Company to new levels," said Dr. Sancilio.
SCI is a vertically integrated pharmaceutical company based in Riviera Beach, Florida focused on cardiovascular, dental and women's health products. SCI's products include Ocean Blue® Professional Omega-3 2100™, chewable and liquid prescription sodium fluorides, and prescription prenatal vitamins.
New Director Profiles
Dr. Alan Dunton
Dr. Dunton has over 25 years of experience as an executive in the pharmaceutical/biotechnology industry. Dr. Dunton is the founder and principal of Danerius, LLC, a consulting firm that works with small to mid-size pharmaceutical companies to guide them through drug development programs, assist them in identifying and evaluating product opportunities, and secure funding or partnering opportunities.
Prior to founding Danerius, Dr. Dunton held numerous positions in major pharmaceutical companies. Most recently, he served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc., and previously served as President and CEO of Metaphore Pharmaceuticals. Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including President and Managing Director of The Janssen Research Foundation. Dr. Dunton also held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc.
Dr. Dunton serves on several boards of directors, including EpiCept Corporation, as Non-Executive Chairman, Targacept, Inc., Oragenics, Inc. and Palatin Technologies Inc.
Dr. Dunton earned an MD from New York University School of Medicine and a BS in Biochemistry from State University School of New York at Buffalo.
Mr. Gray has 37 years of experience with PricewaterhouseCoopers in Boston, Philadelphia, New York, Vancouver and Florham Park, NJ, including 25 years as an Audit Partner. During his time at PwC, Mr. Gray provided services across a range of industries, including life sciences, technology, services and industrial companies, and served clients that included Biogen, Genzyme, Millipore, Sepracor, BearingPoint, Oak Industries, Parametric Technology and Fisher Scientific. From 1986 to 1997, Mr. Gray acted as leader and co-leader of the Price Waterhouse U.S. High Tech practice and from 2007 to 2009 led the PwC U.S. Corporate Governance Group.
Mr. Gray earned a BS from The Wharton School of Business at the University of Pennsylvania and is a Certified Public Accountant.
Mr. Jackson has over 40 years of experience as an executive in the pharmaceutical/biotechnology industry, including 16 years with Mylan Laboratories. Mr. Jackson joined Mylan in 1986 as Vice President of Marketing and Sales. In 1992, Mr. Jackson was promoted to Senior Vice President where he was tasked with the creation of a new Business Development and Strategic Planning Department. In this role, Mr. Jackson was responsible for creation of the Institutional and Branded Divisions of Mylan Laboratories. Mr. Jackson was a member of Mylan's Office of the President and Executive Management Committee until his retirement in 2002.
In 2005, Mr. Jackson established Cobalt Laboratories, Inc., a U.S subsidiary of Arrow Group. Under Mr. Jackson's leadership, Cobalt developed a product line and grew annual revenues to $200M. In 2009, Arrow and Cobalt were sold to Watson Pharmaceuticals for $2.15B.
Mr. Jackson earned a BBA from Texas A&M Kingsville University.
Dr. Dennis Langer
Dr. Langer has over 25 years of experience in the pharmaceutical/biotechnology industry. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity and venture capital fund specializing in the pharmaceutical sector. Previously, Dr. Langer served as President, North America, of Dr. Reddy's Laboratories Limited. From 1994 to 2004, Dr. Langer held several positions at GlaxoSmithKline, including Senior Vice President of Research and Development. Prior to GlaxoSmithKline, Dr. Langer held numerous positions in innovative research and development companies such as Eli Lilly, Abbott and GD Searle. Earlier in his career, he was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships in Psychiatry at Harvard Medical School, George Washington University School of Medicine, and the National Institutes of Health.
Dr. Langer serves on several boards of directors, including Myriad Genetics, Inc., Myrexis, Inc., and Dicerna Pharmaceuticals, Inc., and is an Advisor to Investor Growth Capital. Dr. Langer is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine.
Dr. Langer earned an MD from Georgetown University School of Medicine, a JD from Harvard Law School, and a BA in Biology from Columbia University.
Mr. Perkins is an original Principal, Executive Committee Member and Co-Chief Investment Officer of Lighthouse Partners, a West Palm Beach-based manager of funds of hedge funds. Lighthouse has approximately $5.9 billion under management for institutional and private investors. Previously, Mr. Perkins held several positions at Bermuda-based Trout Trading Management Company, Ltd., including Director of Accounting. Prior to joining Trout, Mr. Perkins served as a business associate with Coopers & Lybrand, LLP.
Mr. Perkins earned a BBA in Accounting from the College of William and Mary and is a Chartered Financial Analyst.
About Sancilio and Company, Inc.
Sancilio and Company, Inc. is a vertically integrated pharmaceutical company focused on the development, manufacture and sale of cardiovascular, dental and women's health products. SCI's products include Ocean Blue® Professional Omega-3 2100™, which contains 2,100 mg of Omega-3 per serving, chewable and liquid prescription sodium fluorides, and prescription prenatal vitamins. SCI's research and development labs and manufacturing facilities are all located in Riviera Beach, Florida.Daren Graham, Chief Legal Officer Sancilio and Company, Inc., (561) 209-2834, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Sancilio and Company, Inc.|
Copyright©2012 PR Newswire.
All rights reserved